Vulvovaginitis refractaria: relevancia clínica de las pruebas de sensibilidad a antifúngicos
DOI:
https://doi.org/10.22529/Palabras clave:
candidiasis vulvovaginal, resistencia a antifúngicos, fluconazol, candida sppResumen
INTRODUCCIÓN: Candidiasis vulvovaginal (CVV) es una infección de alta incidencia. Las fallas en el tratamiento llevan a un aumento de casos refractarios especialmente asociados a especies de Candida no-albicans. OBJETIVO: describir la prevalencia de resistencia antifúngica en aislamientos de flujo vaginal procesados en un laboratorio privado de la Ciudad de Córdoba entre agosto y octubre de 2024. MATERIALES Y METODOS: se procesaron 674 muestras de exudado vaginal para el aislamiento y pruebas de susceptibilidad de levaduras. Se evaluó la sensibilidad a fluconazol según pautas M44 del (CLSI)1 RESULTADOS: De 674 muestras procesadas, 289 fueron positivas para Candida spp., y solo al 40% se les solicitó antifungigrama. Entre estas, se evidenció una resistencia al fluconazol entre el 36% y el 44%. CONCLUSIÓN: Estos hallazgos subrayan la necesidad de incorporar rutinariamente estudios de susceptibilidad antifúngica para optimizar el tratamiento y reducir las fallas terapéuticas en pacientes con CVV recurrente o refractaria.Descargas
Referencias
CLSI M44-Method for Antifungal DiskDiffusion Susceptibility Testing of Yeasts.
Fan S, Liu X, Wu C, Xu L, Li J. Vaginalnystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis.Mycopathologia. 2015;179(1-2):95-101. https://doi.org/10.1007/s11046-014-9827-4
Bradfield Strydom M, Khan S, Walpola RL, Ware RS, Tiralongo E. Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review. Journal of medical microbiology. 2023;72(5). https://doi.org/10.1099/jmm.0.001705
Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert opinion on pharmacotherapy. 2018;19(9):971-7. https://doi.org/10.1080/14656566.2018.1476490
Sun Z, Ge X, Qiu B, Xiang Z, Jiang C, Wu J, et al. Vulvovaginal candidiasis and vaginal microflora interaction: Microflora changes and probiotic therapy. Frontiers in cellular and infection microbiology. 2023; 13:1123026.
Satora M, Grunwald A, Zaremba B, Frankowska K, Żak K, Tarkowski R, et al. Treatment of Vulvovaginal Candidiasis-An Overview of Guidelines and the Latest Treatment Methods. Journal of clinical medicine. 2023;12(16). https://doi.org/10.3390/jcm12165376
Nguyen Y, Lee A, Fischer G. Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy. The Australasian journal of dermatology. 2017;58(4): e176-e81. https://doi.org/10.1111/ajd.12487
Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-Term Outcomes of Women with Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. Journal of lower genital tract disease. 2018;22(4):382-6. https://doi.org/10.1097/LGT.0000000000000413
Hendrickson JA, Hu C, Aitken SL, Beyda N. Antifungal Resistance: a Concerning Trend for the Present and Future. Current infectious disease reports. 2019;21(12):47. https://doi.org/10.1007/s11908-019-0702-9
Chen Z, Jin J, Chen H, Chen Y, Feng S. The bacterial communities in vagina of different Candida species-associated vulvovaginal candidiasis. Microbial pathogenesis. 2023; 177:106037. https://doi.org/10.1016/j.micpath.2023.106037
Lírio J, Giraldo PC, Amaral RL, Sarmento ACA, Costa APF, Gonçalves AK. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. BMJ Open. 2019;9(5): e027489. https://doi.org/10.1136/bmjopen-2018-027489
Leusink P, van de Pasch S, Teunissen D, Laan ET, Lagro-Janssen AL. The Relationship Between Vulvovaginal Candidiasis and Provoked Vulvodynia: A Systematic Review. The journal of sexual medicine. 2018;15(9):1310-21. https://doi.org/10.1016/j.jsxm.2018.07.011
Mushi MF, Olum R, Bongomin F. Prevalence, antifungal susceptibility and etiology of vulvovaginal candidiasis in subSaharan Africa: a systematic review with metaanalysis and meta-regression. Medical mycology. 2022;60(7). https://doi.org/10.1093/mmy/myac037
Waikhom SD, Afeke I, Kwawu GS, Mbroh HK, Osei GY, Louis B, et al. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates. BMC pregnancy and childbirth. 2020;20(1):266.
Maraki S, Mavromanolaki VE, Stafylaki D, Nioti E, Hamilos G, Kasimati A. Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis. Mycoses. 2019;62(8):692-7. https://doi.org/10.1111/myc.12946
Sobel JD. Resistance to Fluconazole of Candida albicans in Vaginal Isolates: a 10-Year Study in a Clinical Referral Center. Antimicrobial Agents and Chemotherapy. 2023;67(5): e00181-23. https://doi.org/10.1128/aac.00181-23
Aniebue UU, Nwankwo TO, Nwafor MI. Vulvovaginal candidiasis in reproductive age women in Enugu Nigeria, clinical versus laboratory-assisted diagnosis. Nigerian journal of clinical practice. 2018;21(8):1017-22. https://doi.org/10.4103/njcp.njcp_25_16
Sobel JD, Sebastian S, Boikov DA. A longitudinal study on fluconazole resistance in Candida albicans vaginal isolates. Mycoses. 2023;66(7):563-5. https://doi.org/10.1111/myc.13582
